Old Web
English
Sign In
Acemap
>
authorDetail
>
Maria Regina C. Flores
Maria Regina C. Flores
Seattle Children's Research Institute
Pathology
Medicine
Cancer
c-Met inhibitor
Phases of clinical research
2
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and safety of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy.
2017
Journal of Clinical Oncology
David Smith
Paul R. Conkling
Donald A. Richards
Maria Regina C. Flores
John Nemunaitis
Thomas E. Boyd
Alain C. Mita
Guillaume de La Bourdonnaye
David Wages
Alice Susannah Bexon
Show All
Source
Cite
Save
Citations (4)
A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with FOLFOX for the treatment of patients (pts) with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach.
2015
Journal of Clinical Oncology
Shubham Pant
Manish R. Patel
Carla Kurkjian
Michael Brian Hemphill
Maria Regina C. Flores
Dana S. Thompson
Johanna C. Bendell
Show All
Source
Cite
Save
Citations (11)
1